The USC Norris Comprehensive Cancer Center is a cancer center owned and operated by the University of Southern California through its Keck School of Medicine.

During the past decade, USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3 conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3" #1 collaborator was "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3" are "Adenocarcinoma" (1 trials), "Breast Cancer" (1 trials), "Carcinoma" (1 trials), "Hypernephroid" (1 trials) and "Nephroid Carcinoma" (1 trials). Many other conditions were trialed in "USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3" in a lesser frequency.

Most popular intervention types in "USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Everolimus" (1 trials), "Everolimus Placebo" (1 trials), "Exemestane" (1 trials), "RAD001(everolimus)" (1 trials) and "TKI258" (1 trials). Other intervention names were less common.

The vast majority of trials in "USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3" are 2 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".